Comparative Pharmacology
Head-to-head clinical analysis: VIRAMUNE versus VIRAMUNE XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIRAMUNE versus VIRAMUNE XR.
VIRAMUNE vs VIRAMUNE XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-nucleoside reverse transcriptase inhibitor (NNRTI); binds directly to HIV-1 reverse transcriptase, causing allosteric inhibition and blocking RNA-dependent and DNA-dependent DNA polymerase activities.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing enzyme inhibition and preventing viral RNA-dependent DNA polymerization.
200 mg orally once daily for 14 days, then 200 mg twice daily; alternatively, 400 mg extended-release once daily for 14 days, then 400 mg extended-release once daily.
400 mg orally once daily for 14 days lead-in, then 400 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 25-30 hours (single dose); 20-25 hours at steady state due to autoinduction. Clinical context: Autoinduction of CYP3A4 reduces half-life after multiple doses.
Terminal elimination half-life 25-30 hours after multiple doses; clinical context: allows once-daily dosing after lead-in phase.
Renal: <5% unchanged; urinary metabolites: ~80% (glucuronides, hydroxylated metabolites); fecal: ~10%.
Renal (81% as metabolites, <5% unchanged), fecal (10% as metabolites).
Category C
Category C
Antiretroviral (NNRTI)
Antiretroviral (NNRTI)